Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) just unveiled an update.
Mochida Pharmaceutical has raised its full-year consolidated forecast for the fiscal year ending March 31, 2026, reflecting stronger-than-expected performance in its pharmaceutical business and higher income from equity-method investments. The company now expects consolidated net sales of ¥115.5 billion, operating profit of ¥9.5 billion, ordinary profit of ¥11.0 billion, and profit attributable to owners of parent of ¥8.4 billion, representing year-on-year growth and sizable increases of 35.7% to 55.6% versus its previous guidance, signaling improved earnings momentum and potentially stronger returns for shareholders.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3964.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company engaged in the development, manufacture, and sale of prescription drugs and related pharmaceutical products. The company operates primarily in the domestic healthcare market, with performance driven by its core pharmaceutical business and earnings also influenced by equity-method investments.
Average Trading Volume: 34,503
Technical Sentiment Signal: Buy
Current Market Cap: Yen126.2B
For a thorough assessment of 4534 stock, go to TipRanks’ Stock Analysis page.